InvestSMART

BLS Pharmaceuticals Limited (ASX: BLS) - Share Price

Current share price for BLS : $1.020 0.035 (3.55%)+

BLS Pharmaceuticals Limited (BLS, formerly Bioxyne Limited) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is an Australian pharmaceutical company focused on the development manufacture and commercialization of medicines final patient dosage forms and active pharmaceutical ingredients.

BLS General Information +

ASX Code BLS
Website http://www.blspharma.com
Industry/Sector Personal Products
Market Cap ($M) 235
BLS Share Price $1.020
Day High $1.030
Day Low $0.980
Last Close $0.985
BLS Share Price Movement $0.04 ( 3.55% )
Prices as at 16:40, 9 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

BLS Pharmaceuticals Limited (BLS) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from BLS Pharmaceuticals Limited (BLS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

BLS Pharmaceuticals Limited (BLS) price-sensitive announcements

BLS - BLS Pharmaceuticals Investor Webinar Presentation
BLS Pharmaceuticals Limited, through its subsidiary Breathe Life Sciences, is a globally r
BLS Pharmaceuticals Limited (BLS)
30 Jul 2026 | 8:57 AM
BLS - Quarterly Activities/Appendix 4C Cash Flow Report
BLS Pharmaceuticals Limited, formerly Bioxyne Limited, reported significant financial and
BLS Pharmaceuticals Limited (BLS)
27 Jul 2026 | 8:52 AM

BLS Pharmaceuticals Limited (BLS) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
BLS Pharmaceuticals Limited (BLS)
ORDINARY FULLY PAID
Consumer Staple $236 Becoming a substantial holder 9 Oct 2026 2:39PM $0.995 $1.020 risen by 2.51%
BLS Pharmaceuticals Limited (BLS)
ORDINARY FULLY PAID
Consumer Staple $236 AGM Date and Director Nominations 7 Oct 2026 9:54AM $0.975 $1.020 risen by 4.62%
BLS Pharmaceuticals Limited (BLS)
ORDINARY FULLY PAID
Consumer Staple $236 Application for quotation of securities - BLS 5 Oct 2026 11:46AM $1.000 $1.020 risen by 2%
BLS Pharmaceuticals Limited (BLS)
ORDINARY FULLY PAID
Consumer Staple $236 Application for quotation of securities - BLS 28 Sep 2026 2:49PM $0.985 $1.020 risen by 3.55%
BLS Pharmaceuticals Limited (BLS)
ORDINARY FULLY PAID
Consumer Staple $236 Initial Director's Interest Notice 15 Sep 2026 8:20AM $1.165 $1.020 fallen by 12.45%
BLS Pharmaceuticals Limited (BLS)
ORDINARY FULLY PAID
Consumer Staple $236 Angus Walker Appointed Alternate Director to Edward Myer 14 Sep 2026 8:25AM $1.180 $1.020 fallen by 13.56%

BLS Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A $15.40 $6.70 3,090.50% 0.80 0.00 0.00% 0.0%
2025A $4.90 $0.20 -450.00% 9.60 0.00 0.00% 0.0%
2024A -$1.41 -$0.10 -57.10% 0.00 0.00 0.00% 0.0%

BLS Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
BLS Pharmaceuticals Limited (BLS) $227M 30.9048 0.0000 0.0000 14.7015 0.0000 0.0000 0.00% 0.00% 0.00%

BLS Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.20 15.20 7.54 0.00
Market 0.37 14.00 1.06 0.74
Sector 0.00 20.30 1.01 0.00

BLS Directors

Name Position Start Date
Mr Angus Walker Alternate Director 14 Sep 2026
Mr Samuel Watson Chief Executive Officer, Managing Director 19 May 2023
Mr Jason Hine Executive Director 19 May 2023
Mr Edward Myer Non-Executive Director 3 Jun 2026
Mr Anthony (Tony) Peng Ho Non-Executive Director, Non-Executive Chairman 30 Oct 2012

BLS Pharmaceuticals Limited (BLS) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
12 May 2026 HO, Anthony (Tony) Buy Indirect Shares 5,000,000 $0.020 $100,000.000
12 May 2026 HO, Anthony (Tony) Exercise Options 5,000,000 $0.020 $100,000.000
19 Mar 2026 WATSON, Samuel Buy Indirect Shares 1,800,000 $0.050 $90,000.000

See all changes in directors' interest & trades for BLS Pharmaceuticals Limited (BLS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

BLS Management

Name Position
Guy Adrian Robertson Company Secretary

BLS Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in BLS Pharmaceuticals Limited (BLS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
57,626,852 (25.02%) BREATHE INTERNATIONAL LIMITED
19,562,562 (8.49%) BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>
15,780,560 (6.86%) Kirkman Trading
13,248,896 (5.75%) Ian Edward Owles

BLS Calendar of Events

Date Event
30 August 2027 Report (Annual)
30 August 2027 Report (Prelim)
25 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.